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Chronic kidney disease is a major public health problem
globally. Despite this, there are fewer high-quality,
high-impact clinical trials in nephrology than other internal
medicine specialties, which has led to large gaps in evidence.
To address this deficiency, the Australasian Kidney Trials
Network, a Collaborative Research Group, was formed in
2005. Since then, the Network has provided infrastructure
and expertise to conduct patient-focused high-quality,
investigator-initiated clinical trials in nephrology. The
Network has not only been successful in engaging the
nephrology community in Australia and New Zealand but
also in forming collaborations with leading researchers from
other countries. This article describes the establishment,
development, and functions of the Network. The article
also discusses the current and future funding strategies
to ensure uninterrupted conduct of much needed clinical
trials in nephrology to improve the outcomes of patients
affected by kidney diseases with cost-effective interventions.
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Chronic kidney disease (CKD) is a major public health
problem in Australia and throughout the world.1 The preva-
lence of CKD has been estimated at between 10 and 15% in
industrialized countries.2–4 End-stage kidney disease (ESKD)
consumes disproportionate health-care resources. In
2011–2012, the Commonwealth of Australia spent 1.6% of
its annual health-care budget to provide treatment to patients
with ESKD, who constituteo0.1% of the entire population.5
The disparate spending of government funds on ESKD care is
mirrored in other developed countries. Annually, the United
States spends 6% of its Medicare budget on its ESKD
program, despite the Medicare ESKD population repre-
sentingo0.2% of the country’s population,6 whereas Taiwan,
another country with a comparatively high prevalence of
ESKD (0.24%),7 spends 7.7% of its annual health-care budget
on the provision of dialysis.8 The presence of CKD is one of
the most potent risk factors for cardiovascular disease. CKD
and ESKD are associated with substantially increased risk
of all-cause and cardiovascular mortality and poor quality
of life.9
Despite the burden of morbidity and mortality and high
health-care costs associated with CKD, the overall number of
published clinical trials in nephrology is the lowest of any
internal medicine specialty (Figure 1).10,11 Moreover, the
quality and coverage of renal clinical trials lag behind other
medical fields.12 Many industry-sponsored trials routinely
exclude patients with significant CKD to maintain a
homogeneous study population and to exclude a potential
confounding effect of CKD on renally excreted agents; those
that do include CKD patients are often designed to address
commercial imperatives rather than clinically important
questions. This contributes to the under-representation of
CKD patients in commercial trials, and has the implication
that outcomes from such trials cannot easily be extrapolated
to a CKD population. Such questions are usually answered by
investigator-initiated trials, which, because of funding con-
straints and limited infrastructural support, are frequently
small, short-duration studies limited to one or a few centers.
A recent evaluation of interventional trials registered on
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ClinicalTrials.gov between 2007 and 2010 found that 50% of
studies enrolled fewer than 70 participants, raising significant
questions around their ability to establish conclusively the
safety and effectiveness of treatments and enable better
decision-making in clinical practice.13 These factors led the
peak nephrology body in Australasia to recognize the need
for infrastructure to support investigator-initiated trials to
address clinically significant issues specific to a CKD
population.
This article provides an overview of the establishment,
development, and functions of the Australasian Kidney Trials
Network (AKTN), a clinical trials network in nephrology
involving centers from Australia and New Zealand.
ESTABLISHMENT OF THE AKTN
The Initiating Dialysis Early and Late study14 was conducted
across 32 centers in Australia and New Zealand and was the
first large-scale, investigator-initiated collaborative clinical
research effort in Australasia in nephrology. A subsequent
cost-effectiveness evaluation involving Initiating Dialysis
Early and Late study participants revealed important
cost-saving information relating to delaying dialysis
commencement, which confirms that well-conducted
clinical trials can provide significant economic benefits to
research-active institutions.9 At the time of trial inception,
limited infrastructure existed to support Australasian
nephrologists in the conduct of clinical trials. To address
the dearth of clinical studies in nephrology, to ensure that the
lessons learnt and momentum generated by the success of the
Initiating Dialysis Early and Late trial were not lost, and to
support research with potentially cost-saving outcomes, the
Australian and New Zealand Society of Nephrology
(ANZSN) and Kidney Health Australia identified the need
for an Australasian-based Collaborative Research Group
(CRG) to drive investigator-initiated clinical trials in the
region. A call for expressions of interest was circulated via the
ANZSN, inviting clinical and academic nephrologists and
public health researchers to become involved in establishing
the Network. Utilizing seed funding provided by these
groups, and advice and assistance from the Australian and
New Zealand Intensive Care Society, the George Institute for
Global Heath, and the National Health and Medical Research
Council Clinical Trials Center, the AKTN (the ‘Network’)
was established in 2005 to address questions of clinical
importance to renal patients and nephrologists. Key opinion
leaders from across Australia and New Zealand were invited
through their ANZSN membership and engaged to form the
inaugural Scientific Committee and Operations Secretariat,
whose roles were to identify clinical research priorities of the
renal community, secure funding for the AKTN, and engage
renal clinicians in trial participation. Engagement was to
occur primarily via distribution of expressions of interest to
the ANZSN membership. In 2005, a National Health and
Medical Research Council enabling grant was able to be
successfully leveraged from initial seed funding, allowing the
first AKTN clinical trial protocols to be developed and the
AKTN website to be published to provide the community
access to AKTN information and resources. This grant also
enabled core AKTN staff to be engaged, specifically an
Operations Manager to run daily financial, contractual, and
personnel matters, a Project Manager to advance protocol
development, a Biostatistician, and an Executive Support
Officer. Additional trial-specific staff (Clinical Research
Associates, Biostatisticians and Data Managers) were engaged
using trial-specific funding. Important milestones for the
AKTN are depicted in the timeline shown in Figure 2.
The AKTN governance structure is depicted in Figure 3.
The Operations Secretariat manages the daily activities of the
Network. Supporting the Operations Secretariat is a Scientific
Committee comprising nephrologists, renal nurses, renal
dietitians, biostatisticians, a public health economist, and
a patient with kidney disease. The Scientific Committee’s
primary responsibility is to ensure that Network trials
maintain a high level of scientific and clinical merit and are
representative of the priorities of the nephrological and
kidney patient community. Further supporting the Opera-
tions Secretariat is an independent Advisory Board that
provides high-level advice on the strategic direction of the
Network, including funding, success measures, education,
and overall Network progress.
AKTN TRIAL DEVELOPMENT: FROM PROPOSAL TO
PUBLICATION
The AKTN provides support to clinician researchers with a
clinical trial concept but without the experience or resources
to implement it. Without the AKTN, early career or
experienced researchers may not be in a position to instigate
clinical trials in nephrology; by providing a central hub from
which trials can be coordinated, the Network offers a more
streamlined approach to renal trials. The services offered to
researchers are given in Table 1.
ACHIEVEMENTS OF THE AKTN
The formation of the AKTN has successfully addressed
previously unmet research needs of the renal community by
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Figure 1 | Number of randomized controlled trials (RCT)
published in nephrology and 12 other specialties of internal
medicine from 1966 to 2002. Reproduced from J Am Soc Nephrol
with permission.10
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appreciably improving clinical trial support, education,
quality, funding, and output (Table 2).
Augmented infrastructure to support research
The Network has accrued a critical mass of trials expertise.
Access to these resources has provided investigators with the
tools to develop, conduct, monitor, analyze, and report on a
clinical trial. The Network has also facilitated the formation
of Trial Management Committees and Data and Safety
Monitoring Boards.
Increased collaboration
It has been proposed that a number of the barriers to
successful completion of clinical trials can be overcome
by multicenter collaboration.10 The AKTN has success-
fully brought together renal units from Australia and
New Zealand, and has had recent success in partnering
with centers in Malaysia and the United Kingdom, owing
to similar research priorities with collaborators in these
countries. In mid-2012, 60 renal units were participating in at
least one AKTN trial, including 45 in Australia and New
Zealand. Furthermore, the AKTN has been invited to engage
Australian and New Zealand sites in four large, multinational
clinical trials by local or overseas-based CRGs (see Table 3).
International research groups collaborating on large-scale
clinical trials have expanded the patient pool available,
thereby increasing the likelihood of achieving recruitment
success and trial completion. This has the additional
advantage of enhancing the heterogeneity of the trial
population, which can increase the generalizability and
external validity of trial results.15 The use of AKTN links
to international CRGs and to national and international
experts in other specialties has also provided access to
international experts in the field of nephrology, cardiology,
statistics, pharmacology, dietetics, nursing, health econo-
mics, and clinical trial conduct for membership on trial Data
and Safety Monitoring Boards and Trial Management
Committees. Collaboration with local academic groups,
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Figure 2 | Important AKTN milestones. AKTN, Australasian Kidney Trials Network; ANZSN, Australian and New Zealand Society of Nephrology;
CRG, Collaborative Research Group; KHA, Kidney Health Australia; NHMRC, National Health and Medical Research Council.
Table 1 | Services offered by the AKTN
Before funding procurement For funded trials
Scientific peer review of trial
proposal
Protocol development and
amendments
Trial design Trial coordination
Protocol development Financial management
Identification of funding sources Contract negotiations
Assistance with funding applications Site management
Access to AKTN Scientific
Committee
Ethics and governance
documentation and correspondence
Assistance with statistical analysis
plans
Investigational product
procurement and management
Development of trial resources
Regulatory reporting
Safety reporting
Trial promotion
Data management
Statistical analysis
Data and safety monitoring
Manuscript preparation and
submission
Abbreviation: AKTN, Australasian Kidney Trials Network.
Table 2 | Achievements of the AKTN
Category Benefit
Support Delivered infrastructure and governance required to conduct
investigator-initiated trials
Promoted research collaborations
Enabled the effective organization of research priorities
Quality Improved the quality of investigator-initiated research in the
region
Funding Increased funding opportunities
Education Promoted renal research in the region
Provided educational and career opportunities in renal
clinical trials
Abbreviation: AKTN, Australasian Kidney Trials Network.
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Health and Medical Research Council Clinical Trials Center,
has contributed substantially to the growth of the Network in
its early years. Increased academic collaboration will enhance
the AKTN’s future ability to conduct high-quality, high-
impact clinical trials.
Establishment of clinical research priorities
Clinical research priorities for the AKTN have been
determined via a combination of (a) evaluation of surveys
of all AKTN clinician and health consumer members; (b)
development of special interest groups in renal transplanta-
tion, hemodialysis, peritoneal dialysis, and chronic kidney
disease; (c) recommendations of the Caring for Australasians
with Renal Impairment (CARI) Guidelines Writing Groups;
and (d) dialog with the Cochrane Renal Group to identify
important gaps in evidence. In conjunction with the broader
renal community, the AKTN Scientific Committee has
established key research priorities to be addressed by
investigator-initiated trials.
Expanded educational and career opportunities for renal
clinician scientists
As a medical specialty, nephrology is experiencing a work-
force shortage in Australasia.16 A survey conducted across
Australian physician trainees in 2009 identified barriers to
medical trainees pursuing nephrology as a career choice, and
suggested that engaging trainees’ research interests may
demystify renal medicine and increase uptake.17 The AKTN
has provided significant educational opportunities to the
nephrology community, particularly targeting Early Career
Researchers with an interest in clinical trial design, conduct,
and the tenets of good clinical practice. Furthermore,
opportunities for participation in clinical trials have been
provided by the AKTN through encouragement of Early
Career Researchers as trial principal investigators and Trial
Management Committee members, and the provision of
scholarships for PhD and Master degree candidates.
Enhanced clinical trial quality
Samuels and Molony18 outlined the importance of
maintaining high standards in several features of clinical
trial design and conduct. The AKTN has provided clinician
investigators access to biostatisticians with proven expertise
and specialist training in clinical trial design and analysis.
In addition, all AKTN trials are conducted with full
International Conference on Harmonization Good Clinical
Practice (ICHGCP) guideline compliance, AKTN staff are
accredited with the Association of Clinical Research
Professionals, and each trial has been assigned an indepen-
dent Data and Safety Monitoring Board to ensure ongoing
data quality and participant safety. The provision of edu-
cational opportunities to clinician investigators, combined
with AKTN’s rigorous standards and operating procedures,
ensures that investigator-initiated renal trials in the region are
conducted ethically and deliver high-quality data.
Increased funding opportunities
Lack of funding availability is the main reason research
studies do not proceed to commencement.19 Furthermore,
research studies that attract external, competitive grants are
Table 3 | AKTN clinical trials: coordinated, facilitated, and endorsed
Trial acronym ANZCTR number
Support
type Trial status
FAVOURED: Fish oil and Aspirin in Vascular access OUtcomes in REnal Disease 12607000569404 Coordinated Recruiting
HONEYPOT: HOney versus Nasal Eradication of staphYlococci for the Prevention Of
Tenckhoff infections in PD
12607000537459 Coordinated Completed
HERO: Handling Erythropoietin-Resistance with Oxpentifylline 12608000199314 Coordinated Completed
ACCORD: Assessment of Carnitine for Clinical Outcomes in Renal Disease 12609000024246 Endorsed Completed
BLOCADE: Beta-blocker to LOwer CArdiovascular Dialysis Events 12609000174280 Coordinated Ongoing
PEXIVAS: Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody
associated systemic vasculitis
Clinicaltrials.gov no.:
NCT00987389
Facilitated Recruiting
ACTIVE: A Clinical Trial of IntensiVE Dialysis Clinicaltrials.gov no.:
NCT00649298
Endorsed Ongoing
IMPROVE-CKD: IMpact of Phosphate Reduction On Vascular End points in Chronic Kidney
Disease
12610000650099 Coordinated Recruiting
ACEi: Ace inhibition for the preservation of renal function and patient survival in kidney
transplantation
Controlled-trials.com
no.: MCT-78844
Facilitated Ongoing
SOLID: The SOdium Lowering In Dialysate Trial 12611000975998 Endorsed Recruiting
TESTING: Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Clinicaltrials.gov no.:
NCT01560052
Endorsed Recruiting
CKD-FIX: a randomized Controlled trial of slowing of Kidney Disease progression From the
Inhibition of Xanthine oxidase
12611000791932 Coordinated Recruiting
TransDiab: A randomized controlled trial of metformin versus gliclizide in overt diabetes
and metformin versus placebo in glucose intolerance in the treatment of NODAT: Feasibility
study
TBA Coordinated In development
Blockade of uremic toxins in prevention of Heart Failure and CKD TBA Endorsed In development
Abbreviations: AKTN, Australasian Kidney Trials Network; ANZCTR, Australian New Zealand Clinical Trials Registry; PD, peritoneal dialysis.
26 Kidney International (2014) 85, 23–30
po l i cy fo rum AT Morrish et al.: Australasian Kidney Trials Network
more likely to achieve publication of their primary results.20,21
By providing resources necessary for competitive grant
application submission to major funding bodies, the AKTN
increases the likelihood of a trial’s commencement, comple-
tion, and subsequent publication, thereby contributing to
the body of clinical trial evidence in the renal specialty and
increasing the opportunity to impact on patient care.
Through its national and global cooperative associations,
the AKTN provides opportunities for linking international
and local researchers on trial management teams, thereby
strengthening funding proposals and boosting the track
record of collaborators.
A National Health and Medical Research Council enabling
grant was successfully leveraged by the AKTN in 2005
following initial seed funding provided by Kidney Health
Australia and ANZSN. Demonstrated network success in key
performance areas, as well as established in-kind support
from the University of Queensland, Queensland Health,
and the George Institute for Global Health, led to a second
National Health and Medical Research Council enabling
grant being awarded in 2010, indicating the importance
placed on the renal clinical trial network by the federal
government funding agency.
Increased renal clinical trial output
Since 2005, 23 clinical trial proposals have been presented
to the AKTN for consideration of coordination, facilitation,
or endorsement, and have undergone review for scientific
quality, clinical merit, and statistical rigor. Of those, seven
have been approved for coordination, two for facilitation (the
AKTN runs the regional arm of an international study), and
five for endorsement (the AKTN provides support/advice but
does not coordinate the trial) (Table 3). All nine coordinated
or facilitated trials are multicenter in nature, and would likely
not have been initiated without the proposer’s access to
network facilities. Completion of the first two AKTN trials
occurred in 2012.
It has been a priority of the AKTN to publish manuscripts
in the areas of clinical trial research results, statistical ana-
lysis plans, trial protocols, systematic reviews, meta-analyses,
and research methodologies. Three trial protocols,22–24
three systematic reviews,25–27 two research methodology
papers,28,29 and one letter to the editor30 have been pub-
lished based on AKTN research activities; a further four
manuscripts have been submitted, and several more are in
preparation. Once current AKTN trials are completed and
outcomes are made available, the publication rate will further
increase.
LESSONS LEARNT BY THE AKTN
The 6 years of AKTN operations have provided insights into
the main challenges experienced in clinical trials, particularly
investigator-initiated trials, as well as the opportunity to
devise solutions to these challenges.
A slower than anticipated recruitment rate is often the
primary challenge in conducting a clinical trial. The AKTN
has identified an effective method to counteract recruitment
difficulties: inclusion of international collaborators and sites
early in the life of the trial. This proactive strategy is used to
prevent slow recruitment rather than wait for international
groups to ‘rescue’ failing trials. Complex trial protocols
can also contribute to recruitment difficulties. A simple trial
design that closely mirrors standard clinical practice and has
minimal restriction by inclusion and exclusion criteria
reduces trial management costs, facilitates participation by
a large number of centers, enables an easier recruitment
process, and has the added advantage of maximizing the trial
generalizability.
The central coordination processes require careful
management to maximize trial success. Realistic budget pro-
jections ensure that trials are not underfunded on commen-
cement, and close monitoring of expenditure and remodeling
of financial requirements as necessary provides the opportu-
nity to identify the need for additional funding procurement
to facilitate trial completion. The longevity of Network
operations is contingent on diversification of revenue
streams, including financing from government, industry,
research foundations and societies, and the provision of
commercial functions such as education and contract
research or management services. In addition to the admin-
istration of trial research grants, close financial management
of routine operational expenditure is essential.
The AKTN promotes a culture of inclusivity, with all
research units encouraged to participate in clinical research
and contribute according to the availability of resources,
thereby fostering engagement within the community and a
sense of ‘ownership’ of the Network. However, this policy is
tempered with the intermittent exclusion of underperform-
ing sites to ensure that resources are used appropriately and
efficiently. Responsible fiscal management in clinical trial
conduct is also demonstrated by the undertaking of small
feasibility or rigorous proof-of-concept trials devised to
inform large-scale trial design and feasibility in a clinical
setting before major financial outlay.
Access to a research legal team with expertise in legal
issues specific to clinical trials is vital for CRGs co-ordinating
multicenter trials. The application of the legal team’s
expertise in contractual negotiations with external stake-
holders ensures the protection of trial participants and
safeguards the intellectual property and interests of investi-
gators.
The daily operational activities of the AKTN provide a
unique insight into the culture of health-care facilities across
Australia and New Zealand. The barriers and hurdles
encountered in conducting clinical trials at these facilities
suggest a widespread perception that clinical research, and
investigator-initiated clinical trials in particular, are a drain
on hospital resources. The recognition of clinical trials as an
integral part of patient care, and the promotion of a tripartite
model of clinical service, research, and teaching, is an urgent
necessity requiring a widespread paradigm shift in how
research is approached within hospitals.
Kidney International (2014) 85, 23–30 27
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FUTURE PRIORITIES OF THE AKTN
The AKTN will continue to progress renal research in the
region by facilitating investigator-initiated clinical trials
across Australia and New Zealand. Priorities in the imme-
diate future will be to publish the first AKTN clinical
trials, continue educational and promotional activities,
strengthen national and international collaborations, and
engage Australian/New Zealand Nephrologists in renal
research.
Trials
With seven coordinated or facilitated trials currently active, a
primary priority of the Network is completing the first of
these and publishing clinical trial results to inform clinical
practice. Research priorities for future trials will continue to
be focused on trials that deliver patient-centered outcomes,
have hard-clinical end points with the potential to have an
impact on and improve clinical care, and include quality-of-
life assessments. Incorporating cost-effectiveness assessments
and health economic evaluations will remain critical to
inform policy designed to mitigate continuing economic
challenges surrounding health care.
Refining operational processes
The importance of simplified protocols that closely mirror
standard practice of clinical care for renal patients has
been identified through the AKTN experience. Simplified
protocols help manage cost by reducing the number of
assessments required and, where possible, removing investi-
gations extraneous to usual care, and therefore requiring
additional funding through the Network. Protocols using
schedules of assessments in line with standard clinical care
allow trial assessments to be conducted at usual clinic visits
instead of imposing extra appointments on staff and
participants. Simplified protocols that are uncomplicated
for clinical staff and participants also improve site and
participant compliance, which aids the generalizability of
trial results, and thus will continue to be a priority for AKTN
trials. Responsible financial management will also remain
a focus, as the Network continues to make clinical trials
financially viable in the region to offer the best possible
care for renal patients, as well as exposure to the latest
evidence for Renal Physicians. This will include making
trials cost-neutral to participating sites, assisting research
units to negotiate costs with hospital-based services such
as pathology and pharmacy, and lobbying for adequate
funding for trial-specific costs and infrastructural support
for units participating in investigator-initiated clinical
trials. More emphasis will also be placed on the conduct
of rigorous feasibility surveys and feasibility trials at units
before commencing larger trials with hard-clinical end
points and substantial recruitment targets. This will serve
to save resources in the long term by only moving forward
with feasible trials that can realistically expect to be
completed in a suitable time frame and by using appropriate
resources.
Energizing the renal research community
Several strategies to engage and energize the nephrology
community in the region have been identified and adopted
by the AKTN. It will be imperative to maintain these
approaches, as the success of the AKTN relies on an engaged
membership base and enthusiastic support of, and participa-
tion in, its research activities. Strategic engagement of site
personnel includes the following: (1) ensuring a geographical
balance of Trial Management Committee members to drive
trials in their local state or district; (2) inclusion of Early
Career Researchers on Trial Management Committees to
perpetuate clinical trials interest and skills in the region; (3)
placement of renal nurses on Trial Management Committees
to encourage their input into recruitment and trial conduct
at sites; (4) encouraging site staff to engage members of the
hospital-based workforce outside the core trials group,
including Dialysis Nurses, Vascular Access Coordinators,
and Pharmacists, to encourage cooperation and promote
efficiencies on site; (5) conducting regular Steering Commit-
tee meetings to provide a voice to local Investigators and
Study Coordinators on trial progress and issues; and (6)
developing an inclusive publication policy that acknowledges
the input of all trial site staff, including the Investigator and
Research Nurse/Study Coordinator.
The AKTN has a responsibility to the nephrology
community to educate its stakeholders in clinical trial design,
conduct, and good clinical practice. Formal educational
opportunities, including scholarships for the higher research
degrees of PhD and Masters in Public Health, will continue
to be offered, as well as regular workshops targeting specific
aspects of trial design and conduct. Informal educational
opportunities, such as involvement on Trial Management
Committees and assistance through AKTN trial endorse-
ment, will also be available to researchers. The AKTN will
continue to work with other trial networks to promote
clinical trials as a career stream for Early Career Researchers.
Engaging kidney patients
Patient-centered outcomes have always been a focus of AKTN
trials. As the Network has progressed, representatives of the
kidney patient community have been included on core
AKTN committees to ensure that Network activities are
representative of the community’s needs. Quality-of-life
outcomes that are meaningful for kidney patients will
continue to feature in AKTN trials.
Sustainable funding
The largest threat to the future of clinical trial CRGs is
ongoing funding for core operations. The UK’s National
Institute for Health Research implemented a Clinical
Research Network in 2008 to provide funding and network
support to investigator-initiated trials in the United Kingdom
(http://www.crncc.nihr.ac.uk/). Unlike the Australian model
where research funding is sourced via a time-consuming,
annual competitive federal government grant process for
individual investigators or ad hoc funding made available
28 Kidney International (2014) 85, 23–30
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from participation in pharmaceutical company sponsored
research, research units in the UK are encouraged to
participate in research through the provision of infrastruc-
tural support directly from the department of health in the
form of clinical research personnel to facilitate investigator-
initiated trial design and conduct. Although it is yet to be
formally evaluated whether this resource allocation has been
successful in increasing clinical trial quality and output, the
UK Clinical Research Network has been identified as world-
class infrastructure that has improved clinical trial uptake by
participants through raising public awareness of the im-
portance of clinical trials.31 The AKTN provides personnel
and educational support to renal trials in Australia and
New Zealand, but in the absence of a funding model similar
to the UK Clinical Research Network, its sustainability is in
jeopardy. The AKTN aims to join with other clinical trial
networks to lobby government funding bodies to recognize
clinical trials as part of routine clinical care to allow provision
of world-class, evidence-based clinical care to Australian and
New Zealand patients. This campaigning is to be at both
state and federal health department levels, via the National
Health and Medical Research Council, in conjunction with a
working group established at a Medical Journal of Australia
symposium, and directly to the relevant ministers.
National and International collaborations
To increase recruitment success, international collaboration
will continue to be a priority for individual trials, as will
partnering with other national academic research groups to
improve research efficiencies and output. An important goal
of the AKTN is membership of a global clinical trials
consortium consisting of multiple clinical trial networks that
connect in order to (1) identify international research and
clinical priorities, (2) provide a larger pool of renal patients
available for trials, and (3) avoid duplication of research trials
and development of methodologies. The AKTN has already
partnered with international researchers to facilitate an ANZ
arm of existing trials (see Table 3—PEXIVAS and ACEi), and
to expand AKTN-led trials to overseas sites to improve
recruitment rates and generalizability of outcomes (Table 3—
FAVOURED, ACTIVE, and IMPROVE-CKD). A formalized
model of international collaboration would streamline this
process for the future, saving time in setting up contractual
and logistical arrangements. A proposed model of a global
trials consortium would include a joint funding model, and is
outlined in Figure 4.
SUMMARY
The aim of the AKTN is to conduct investigator-driven,
patient-focused clinical research directed to improving
patient outcomes. As a CRG established to facilitate and
promote renal clinical trials in the region, the AKTN strives
to ensure that Australian and New Zealand Investigator-
initiated research is conducted in compliance with ICH GCP,
and is held to a high standard of quality. The Network has a
role in educating renal physicians, nurses, and allied health
professionals in trial design and conduct. The objective of the
AKTN is to increase nephrology research output from the
region, reduce the dearth of clinical evidence in the specialty,
and be an important link for international collaboration,
with the ultimate aim of improving health outcomes for
patients with kidney disease.
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